Implications of Expanded Biosimilar Use in the United States’ Dermatology, Gastroenterology, and Rheumatology Markets Highlighted in New Spherix Study
232 US specialists provided feedback on their use and perceptions of biosimilar agents and their impact on the total treatment landscape EXTON, Pa., July 7, 2022 /PRNewswire/ – Biosimilars are biopharmaceutical products that are nearly identical copies of drugs that have previously been licensed (reference products), with no clinically meaningful efficacy and safety differences from […]
High Unmet Needs Remain in Nephrology Despite Newly Approved Treatment Options According to Latest Research from Spherix Global Insights
Launch data tracking the market receptivity for Korsuva (Vifor/Cara Therapeutics), Kerendia (Bayer), Lupkynis (Aurinia Pharmaceuticals), and Tarpeyo (Calliditas) unveils gaps in patient care EXTON, Pa., June 29, 2022 / PRNewswire / – A survey of 124 US nephrologists, conducted just last week, identifies acute kidney injury (AKI), diabetic kidney disease (DKD), and polycystic kidney disease […]
European Nephrologists Lead the Way with Adoption of Astellas/FibroGen’s HIF-PH inhibitor, EVRENZO (roxadustat), for Anemia of CKD Treatment in Both Dialysis and Non-Dialysis Settings
Recent endorsement of Evrenzo by the National Institute for Health and Care Excellence (NICE) could be a catalyst for further use as alternative to erythropoietin stimulating agents (ESAs) EXTON, Pa., June 27, 2022 / PRNewswire / – The European regulatory authorities tend to be moving in a different direction than U.S. Food and Drug Administration […]
Lilly and Boehringer’s Jardiance Poised for Challenge to AZ’s Market Leader Farxiga in Chronic Kidney Disease: Spherix
Life science launch analyst Spherix reached that conclusion after analyzing the results of two surveys—one of 104 U.S. nephrologists and another of 330 nephrologists, cardiologists, endocrinologists and primary care doctors. While Farxiga is currently the SGLT2 inhibitor of choice among nephrologists, Spherix found Jardiance’s early trial stop has made an impression: Nearly 70% of the kidney specialists […]
US Dermatologists’ Lack of Success with Current Treatment Options in Vitiligo Paves the Way for Pipeline Advanced Systemic Agents to Disrupt the Market, According to Spherix Global Insights
Dermatologists are most enthused about the potential utility of the JAK inhibitor class, including Incyte’s Opzelura, AbbVie’s Rinvoq, Pfizer’s ritlecitinib, and Incyte’s INCB54707 EXTON, Pa., June 15, 2022 /PRNewswire/ — Vitiligo is a disease that causes loss of skin color in patches when cells that produce melanin die or stop functioning.1 Spherix recently surveyed 101 US dermatologists […]
New Research on Alopecia Areata Reveals Vast Potential for Eli Lilly’s Recently Approved Olumiant Across Both the US and EU5, According to Spherix Global Insights
US and EU5 dermatologists report the availability of an oral JAK inhibitor would make a significant change in their treatment decisions moving forward EXTON, Pa., June 22, 2022 /PRNewswire/ — Spherix recently surveyed 200 EU-based dermatologists across France, Germany, Italy, Spain, and the UK and followed up with ten qualitative interviews to assess the current and future […]
Spherix Research Reveals Rheumatologists Taking the Lead Over Nephrologists in Both BENLYSTA (GlaxoSmithKline) and LUPKYNIS (Aurinia) Patient Initiations in Lupus Nephritis
Nephrologists and rheumatologists are approaching the new products from very different perspectives EXTON, Pa., June 17, 2022 /PRNewswire/ —With the approvals of GlaxoSmithKline’s Benlysta in lupus nephritis (LN) at the end of 2020 and Aurinia’s Lupkynis at the beginning of 2021, practitioners now have valuable new treatment options to battle this complex condition. Spherix has been […]
New Spherix Study Reveals Jardiance (Lilly/Boehringer Ingelheim) Has Potential to Challenge Farxiga (AstraZeneca) Lead Among the Non-Diabetic CKD Population
Cross-specialty analysis on CKD and DKD patient management and evolving use of SGLT2 inhibitors shows market may be poised for a shift EXTON, Pa., / June 16, 2022/PRNewswire – As the chronic kidney disease (CKD) and diabetic kidney disease (DKD) treatment landscapes rapidly evolve, nephrologists are providing important insights to explain their increasing use of […]
Spherix Global Insights Will Begin Tracking the Launch of Sanofi/Regeneron’s Dupixent for the Treatment of Eosinophilic Esophagitis
Will the first and only FDA-approved therapy indicated for EoE fill the treatment void expressed by gastroenterologists? EXTON, Pa., June 16, 2022 /PRNewswire – On May 20, 2022, the FDA approved Sanofi/Regeneron’s Dupixent, the first therapy indicated to treat eosinophilic esophagitis (EoE). In response, Spherix Global Insights, an independent market intelligence firm, is initiating their […]
Novartis’ Cosentyx and Eli Lilly’s Taltz Remain Leaders in US and EU5 Psoriatic Arthritis Switching Market, but Janssen’s Tremfya and AbbVie’s Skyrizi Are Picking Up Steam, Spherix Reports
Rheumatologists are more likely than PsA-treating dermatologists to cycle TNFs prior to introducing an alternative mechanism of action agent EXTON, Pa., June 14, 2022 / PRNewswire/ — Spherix Global Insights, a leading market intelligence firm specializing in immunology-based research and insights, recently published several large-scale patient audits focused on psoriatic arthritis (PsA) patients recently switched […]
